Educating Patients on Complications Associated with CAR T-Cell Therapy
The panel provides clinical insights on talking with patients about complications associated with CAR T-cell therapy.
- Dr Park: What protocols and processes do you have in place at the community practice to continue monitoring and managing potential long-term complications or adverse events associated with CAR T-cell therapy?
- How do you approach monitoring for and managing late-onset neurotoxicity or other long-term adverse effects that may occur after the patient transitions back to the community setting?
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
